Home » Stocks » AZYO

Aziyo Biologics, Inc. (AZYO)

Stock Price: $11.58 USD 0.71 (6.53%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $12.00 +0.42 (3.63%) May 7, 7:24 PM
Market Cap 112.50M
Revenue (ttm) 42.68M
Net Income (ttm) -25.34M
Shares Out 7.09M
EPS (ttm) -8.88
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $11.58
Previous Close $10.87
Change ($) 0.71
Change (%) 6.53%
Day's Open 11.70
Day's Range 10.89 - 12.39
Day's Volume 19,899
52-Week Range 9.31 - 18.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SILVER SPRING, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated prod...

3 days ago - GlobeNewsWire

SILVER SPRING, Md., April 28, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pr...

1 week ago - GlobeNewsWire

SILVER SPRING, Md., April 26, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pr...

1 week ago - GlobeNewsWire

SILVER SPRING, Md., April 20, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pr...

2 weeks ago - GlobeNewsWire

SILVER SPRING, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pr...

2 months ago - GlobeNewsWire

SILVER SPRING, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

2 months ago - GlobeNewsWire

SILVER SPRING, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

2 months ago - GlobeNewsWire

SILVER SPRING, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

2 months ago - GlobeNewsWire

SILVER SPRING, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

2 months ago - GlobeNewsWire

SILVER SPRING, Md., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

3 months ago - GlobeNewsWire

SILVER SPRING, Md., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

5 months ago - GlobeNewsWire

SILVER SPRING, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated pro...

5 months ago - GlobeNewsWire

About AZYO

Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device; and cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and ... [Read more...]

Industry
Medical Devices
IPO Date
Oct 8, 2020
Stock Exchange
NASDAQ
Ticker Symbol
AZYO
Full Company Profile

Financial Performance

In 2020, AZYO's revenue was $42.68 million, a decrease of -0.51% compared to the previous year's $42.90 million. Losses were -$21.83 million, 82.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for AZYO stock is "Strong Buy." The 12-month stock price forecast is 20.00, which is an increase of 72.71% from the latest price.

Price Target
$20.00
(72.71% upside)
Analyst Consensus: Strong Buy